ACTU Stock Price | Actuate Therapeutics, Inc. Common stock P/E, Revenue, EPS, & Forecasts

Actuate Therapeutics, Inc. Common stock • ACTU

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Actuate Therapeutics, Inc. Common stock

Ticker

ACTU

Trading on

NASDAQ

ISIN

US0050831009

Industry

Biotechnology

Sector

Healthcare

CEO

Daniel M. Schmitt

Headquarters

1751 River Run, Fort Worth, TX, United States, 76107

Employees

Website

https://actuatetherapeutics.com

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Metrics

BasicAdvanced

Market cap

$153M

P/E ratio

EPS

-$1.85

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

Ex dividend date

Price & volume

Market cap

$153M

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

Earnings

EPS

-$1.85

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$11.73

52-week Low

$5.51

50-day moving average

$8.27

200-day moving average

$8.27

Short ratio

0.06

Short %

0.00%

Management effectiveness

ROE (TTM)

0.00%

ROA (TTM)

0.00%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

19.1M

Float

0.5M

Insiders %

19.10%

Institutions %

52.21%

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.34

Q2 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-6M

∞%

Q3 • 24

$0M

$-6.4M

∞%

Q4 • 24

NaN%

7.96%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$14.3M

$8.9M

62.43%

Q3 • 24

$9.3M

$9.2M

98.88%

Q4 • 24

34.67%

3.48%

58.39%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-9.1M

$22.3M

$-9.1M

Q3 • 24

$-4.8M

$-0.1M

$-4.8M

Q4 • 24

47.84%

100.49%

47.84%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Actuate Therapeutics, Inc. Common stock share?

Actuate Therapeutics, Inc. Common stock shares are currently traded for undefined per share.

How many shares does Actuate Therapeutics, Inc. Common stock have?

Actuate Therapeutics, Inc. Common stock currently has 19.1M shares.

Does Actuate Therapeutics, Inc. Common stock pay dividends?

No, Actuate Therapeutics, Inc. Common stock doesn't pay dividends.

What is Actuate Therapeutics, Inc. Common stock 52 week high?

Actuate Therapeutics, Inc. Common stock 52 week high is $11.73.

What is Actuate Therapeutics, Inc. Common stock 52 week low?

Actuate Therapeutics, Inc. Common stock 52 week low is $5.51.

What is the 200-day moving average of Actuate Therapeutics, Inc. Common stock?

Actuate Therapeutics, Inc. Common stock 200-day moving average is $8.27.

Who is Actuate Therapeutics, Inc. Common stock CEO?

The CEO of Actuate Therapeutics, Inc. Common stock is Daniel M. Schmitt.

How many employees Actuate Therapeutics, Inc. Common stock has?

Actuate Therapeutics, Inc. Common stock has 10 employees.

What is the market cap of Actuate Therapeutics, Inc. Common stock?

The market cap of Actuate Therapeutics, Inc. Common stock is $153M.

What is the P/E of Actuate Therapeutics, Inc. Common stock?

The current P/E of Actuate Therapeutics, Inc. Common stock is null.

What is the EPS of Actuate Therapeutics, Inc. Common stock?

The EPS of Actuate Therapeutics, Inc. Common stock is -$1.85.

What is the PEG Ratio of Actuate Therapeutics, Inc. Common stock?

The PEG Ratio of Actuate Therapeutics, Inc. Common stock is null.